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A powerful molecular synergy between mutant Nucleophosmin
and Flt3-ITD drives acute myeloid leukemia in mice
Leukemia (2013) 27, 1917–1920; doi:10.1038/leu.2013.77
Acute myeloid leukemia (AML) is the commonest myeloid
malignancy, yet there has been little therapeutic progress for this
disease in decades, and only 25–30% of patients survive long
term.1 This reflects its pathogenetic complexity and the fact that
the molecular basis of its largest cytogenetic subgroup, AML with
a normal karyotype (AML-NK), was obscure until recently. Recent
advances in DNA sequencing have revealed that AML-NK is
molecularly heterogeneous with 430 genes recurrently targeted
by somatic mutations in this disease.2 What is also evident is that
each individual case of AML-NK appears to harbor only a small
number of coding driver mutations, often as few as three and
usually no more than five.2,3 Furthermore, it is manifest that the
precise combination of driver mutations in the genome of each
AML impacts on its salient features, including responsiveness to
treatments and prognosis.3
These observations provide a sound starting point for systematic
mechanistic studies to understand the pathogenesis and improve
the treatment of AML-NK. Carefully designed mouse models are
the gold standard in the study of normal and malignant
hemopoiesis, and are already instructing our understanding of
AML-NK.4,5 Here, we report that the two most commonly co-
occurring somatic mutations in AML, namely Nucleophosmin
(NPM1) exon 12 mutations (NPM1c) and internal tandem
duplications of FLT3 (FLT3-ITD), cooperate explosively to induce
AML in knock-in mice. In revealing this striking molecular
synergy, our work offers a basis for the frequent co-occurrence
of these two mutations and provides a valuable model for in-depth
studies of the pathogenesis and treatment of this large subgroup
of AML.
NPM1 is a nucleolar phosphoprotein involved in many cellular
processes. For many of its roles, it relies on its ability to shuttle
between the nucleolus, nucleus and cytoplasm using subcellular
localization signals.6 This ability is impaired in 30% of AMLs as a
result of NPM1c mutations, which disrupt the nucleolar localization
signal of NPM1 and generate a nuclear export signal in its place.7
Mutant NPM1 is known to bind to and alter the subcellular
distribution of several proteins, including HEXIM1, p19Arf and
nuclear factor-kB;8 however, the relevance of these interactions to
AML is unclear. FLT3-ITD mutations occur in 20–25% of AML9 and
result in ligand-independent receptor dimerization and constitutive
FLT3 signaling,10 and are associated with an increased risk of
relapse. Moreover, patients with low or absent levels of wild-type
(WT) FLT3, consistent with loss-of-heterozygosity (LOH) for this
locus, have a particularly poor outcome.9
Recently, we described a conditional knock-in mouse model of
NPM1c mutations and demonstrated that one-third of mice
developed delayed-onset AML, suggesting a requirement for
cooperating mutations. We went on to show that insertional
mutagenesis with transposons led rapidly to AML in 80% of
Npm1c mice, in association with specific recurrent mutations
including activating insertions in Csf2 and Flt3.4 Flt3-ITD
homozygous mutant mice exhibit enhanced proliferation and
survival properties in hemopoietic progenitors and develop a late-
onset disease akin to chronic myelomonocytic leukemia.11
To study the combined effects of NPM1c with FLT3-ITD we
crossed conditional Npm1flox cA/þ with constitutive Flt3ITD/þ to
generate Npm1flox cA/þ ; Flt3ITD/þ double heterozygous mice, then
crossed into Mx1-Cre transgenic mice to induce recombination
of Npm1flox cA in hematopoietic stem cells.4 The Mx1-Cre
allele requires induction by interferon, usually achieved
by intraperitoneal injection of polyinosinic-polycytidylic acid
(pIpC). However, we observed universal and rapid emergence of
AML (myeloid leukemia with maturation) in uninjected
Npm1flox cA;FLT3ITD/þ ;Mx1-Creþ mice (hereafter referred to as
‘Npm1c/Flt3-ITD mice’). Mx1-Cre is known to ‘leak’ in 2–4% of
hemopoietic stem/progenitor cells,12 and this was sufficient to
rapidly generate AML from double mutant cells signifying a striking
cooperativity between Npm1c and Flt3-ITD. The presence of the
cytoplasmic NPM1 was confirmed on protein blots (Figure 1a).
All Npm1c/Flt3-ITD mice developed AML and became moribund
aged 31–68 days (median 49 days; n¼ 29). By contrast, no case of
AML was observed in Npm1flox cA;Mx1-Creþ mice (hereafter
referred to as ‘Npm1c mice’; n¼ 30, of which 15 received pIpC
aged 6–8 weeks), FLT3ITD/þ mice (hereafter referred to as ‘Flt3-ITD
mice’; n¼ 34) or WT mice (WT, n¼ 29) aged to at least 8 months
(Figure 1b). Weekly blood counts from 19 mice with each
genotype showed a progressive increase in blood leukocyte
counts in Npm1c/Flt3-ITD mice, to more than 25-fold that of
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age-matched control littermates, whereas the hemoglobin and
platelet counts were significantly reduced (Figure 1c).
Interestingly, Npm1c/Flt3-ITD siblings/littermates often pro-
gressed to AML at different rates or developed more/less
aggressive disease. To explain this observation we hypothesized
that, as seen in human AML, LOH for Flt3-ITD may be responsible.
We found evidence for significant spontaneous loss of the WT Flt3
allele in blood samples from Npm1c/Flt3-ITD mice and a tendency
for higher blood leukocyte counts (Figure 1d) when LOH was
present. LOH was also seen in bone marrow and spleen but not
tail DNA, in keeping with somatic loss of the WT allele in leukemic
cells (Figure 1d). At the time mice became sick with AML, LOH was
detected in 12 of 15 spleen samples tested.
Flow cytometric analysis of blood samples demonstrated, in
Npm1c/Flt3-ITD mice, a population of blasts/immature cells with
low side scatter (SSC) and CD45dim (Figure 2a) and a large number
of single Mac1þ precursors (Figure 2b). In addition, we also
observed an increased number of mature myeloid (Gr1þ /
Mac1þ ) cells in Npm1c/Flt3-ITD mice, indicating that any
maturation block was incomplete (Figure 2b). The relative
numbers of circulating B (B220þ ) and T (CD3þ ) lymphocytes
were reduced (data not shown). To assay their self-renewal
potential, bone marrow cells from Npm1c (n¼ 4), Flt3-ITD (n¼ 4),
WT (n¼ 4) and Npm1c/Flt3-ITD (n¼ 4) were studied in serial
replating assays. Npm1c/Flt3-ITD cells gave rise to significantly
more colonies at first and subsequent platings than any other
genotype (Figure 2c), demonstrating a significantly increased self-
renewal potential.
Blood smears from sick mice confirmed the presence of blasts,
and histological sections demonstrated widespread infiltration of
solid organs by abnormal myeloid cells (Supplementary Figure S1).
Cells infiltrating the bone marrow and spleen were Gr1þ /Mac1þ
or Gr1 /Mac1þ , and there were increased numbers of Mac1þ /
cKitþ cells compared with other genotypes (Supplementary Figure
S2). Compared with single mutant and WT mice, sick Npm1c/Flt3-
ITD mice had marked splenomegaly (0.95±0.27g vs 0.13±0.02g;
Po0.0001) and hepatomegaly (2.33±0.26g vs 1.6±0.17g,
Po0.0001) at the time of death. Npm1c/Flt3-ITD leukemias
were transplantable into both syngeneic and NOD SCIDg mice
demonstrating their true neoplastic nature (data not shown).
AML is a molecularly and clinically heterogeneous disease and
recent studies have revealed that this heterogeneity is derived, to
a large extent, from the specific combinations of somatic driver
mutations present in individual cases. Here, we show that the
combination of Npm1c and Flt3-ITD, the two most commonly
co-occurring AML mutations, is rapidly and universally
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Figure 1. Npm1c and Flt3-ITD collaborate to drive rapid-onset leukemogenesis with frequent occurrence of Flt3 LOH. (a) Npm1 mutant protein
(arrow) accumulates in the cytoplasm of spleen cells collected from 3-week-old Npm1c/Flt3-ITD, but not Npm1c or Flt3-ITD single-mutant mice.
(b) Kaplan-Mayer survival plots showing the rapid demise of Npm1c/Flt3-ITD mice compared with all other genotypes. (c) Serial blood counts
highlight a consistent explosive increase in blood leukocytes counts (WBC) between 4 and 7 weeks in Npm1c/Flt3-ITD mice (left) and the
markedly abnormal WBC, platelet count (Plts) and hemoglobin concentration (Hb) of sick leukemic Npm1c/Flt3-ITD mice compared with
age-matched control mice. (d) Loss of the Flt3 WT allele in blood DNA from Npm1c/Flt3-ITD AMLs is demonstrated as loss of intensity of the
Flt3-WT PCR band. By contrast, constitutional tail DNA shows no LOH. In these three littermates (19.1a–c), the extent of Flt3-LOH associates
with the degree of leukocytosis (N¼nuclear lysate, C¼ cytoplasmic lysate, OCI-AML3 lysate as positive control, w nonspecific band).
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leukemogenic in knock-in mice. These findings are particularly
striking in light of the fact that, in isolation, both Npm1c4 and Flt3-
ITD11 mutations have relatively subtle effects on mouse
hemopoiesis and lead to leukemia or a myeloproliferative
disorder only after prolonged latencies and in a minority of mice.
What is most remarkable about our findings is the very
short latency of AML in Npm1c/Flt3-ITD mice, which suggests
either: (i) that the two mutations are sufficient to promote AML in
this strain of mice (C57BL6/N) or (ii) that additional mutations are
acquired very rapidly in the pool of cells susceptible to leukemic
transformation. The later possibility is supported by the fact that at
least one type of somatic mutation, namely LOH for Flt3-ITD, was
frequently observed in our mouse AMLs over this short time span.
We recently reported that Npm1c can generate AML in collabora-
tion with, amongst others, activating insertions of the GrOnc
transposon in intron 9 of mouse Flt3. These insertions led to
aberrant expression of a Flt3 messenger RNA predicted to code for
an amino-terminal truncated version of Flt34 which, like Flt3-ITD,
was thought to be constitutively active. Most of these murine
AMLs harbored additional transposon insertions thought to be
important in leukemogenesis. Thus, at this stage it appears
more likely that additional mutations may be required for
leukemogenesis in our Npm1c/Flt3-ITD mice, but this cannot be
stated unequivocally.
In interesting contrast to our present work, a recent report
demonstrated that the combination of Flt3-ITD with NUP98-
HOXD13 in mice led to AML after a much longer latency (median
95 days),14 despite the fact that, unlike Npm1c, NUP98-HOXD13
alone leads to a highly penetrant myelodysplastic syndrome with
a high risk of leukemic transformation. This relative delay is
particularly intriguing as NUP98-HOXD13 can promote leukemic
transformation in association with simple overexpression of WT
FLT3.15 By contrast, in two large transposon-mediated insertional
mutagenesis screens, one published4 and one ongoing, we never
observed transposon insertions leading to simple Flt3
overexpression amongst 4100 mouse Npm1c þ ve AMLs.
Notwithstanding the above, our observations emphasize the
remarkable complementarity between Npm1c and Flt3-ITD. In the
context of a stochastic model for AML pathogenesis,2 this potent
molecular synergy goes some way toward explaining why NPM1c
and FLT3-ITD co-occur so frequently and make the model
described here a valuable tool for the study of the pathogenesis
and treatment of one of the largest molecularly defined
subgroups of AML.
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Figure 2. Expansion of circulating myeloid cells in Npm1c/Flt3-ITD mice culminating to aggressive AML. (a) Representative flow cytometric
analysis of peripheral blood from 7-week-old WT, Npm1c, Flt3-ITD and Npm1c/Flt3-ITD mice shows the presence of a low SSC; CD45dim
population of immature/blast cells in double mutant mice and (b) an increase in both mature granulocytic (Gr1þ /Mac1þ ) and monocytic
(Gr1 /lo/Mac1þ ) populations. (c) Colony-forming assays of BM cells derived from WT and mutant mice showing a markedly increased
replating ability of Npm1c/Flt3-ITD cells compared with other genotypes, indicative of an increased self-renewal potential. As we described
before, a lesser increase in replating ability is observed with Npm1c cells.
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Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K
inhibitor in relapsed/refractory B-cell malignancies
Leukemia (2013) 27, 1920–1923; doi:10.1038/leu.2013.79
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma
(MCL) are incurable B-cell malignancies usually responsive to initial
immunochemotherapy, but virtually all patients experience
relapse. Salvage therapy choices for relapsed/refractory disease
are often limited by resultant cytopenias and acquired drug
resistance. The current priority in these B-cell malignancies,
therefore, is to develop agents with novel mechanisms of action
that are selective for tumor cells, overcome shared patterns of
acquired drug resistance and exhibit limited toxicities.
Styrylbenzylsulfones are a new family of non-ATP-competitive
anticancer agents that induce apoptosis in a variety of tumor cell
lines, including those resistant to many chemotherapy agents.1,2
As a class, styrylbenzylsulfones inhibit cell cycle progression
and induce mitotic arrest of tumor cells with less toxicity to
normal human cells.3,4 ON 01910.Na (rigosertib) is a styryl
sulfonyl compound that demonstrated inhibition of
phosphatidylinositol-3-kinase (PI3K), preferentially targeting the
PI3Ka and PI3Kb isoforms, and triggered apoptosis via the release
of cytochrome c from mitochondria in MCL cell lines.3 Rigosertib’s
mechanism of action was initially considered to include inhibition
of polo-like 1 kinase,4 but evidence for direct inhibition was not
confirmed in subsequent studies5 and its antimitotic activity may
rely on the phosphorylation of mitosis coordinator RanGAP1
SUMO1.6 First-in-man studies of rigosertib in solid tumors
demonstrated excellent tolerability with limited hematologic
toxicity.7 Rigosertib has also demonstrated preclinical and early
clinical activities in myelodysplastic syndromes (MDS),8,9 and it is
currently being tested in a randomized phase III trial in patients
with relapsed/refractory MDS (NCT01241500).
We have previously reported that rigosertib induces rapid
apoptosis in CLL cells with the relative sparing of normal B-cells
and T-cells.10 We demonstrated that the in vitro activity of rigosertib
involved a dual mechanism of inhibition of PI3K pathway signaling
coupled with the induction of an oxidative stress response.
Importantly, activity of rigosertib was equally observed against
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